类风湿性关节炎药物治疗的进展

Pharmacotherapy of rtaeumatoid arthritis

近年来,随着类风湿性关节炎发病机制及某些致炎因子的发现,出现了一系列新药。环氧合酶-Ⅱ特异性抑制剂与传统的非甾体类抗炎药相比具有疗效好、副作用小的优点;早期联合使用改变病情性抗风湿药在近期内有较好的临床疗效。此外重组可溶性肿瘤坏死因子受体融合蛋白 (etanercept)、人体抗肿瘤坏死因子-α单克隆抗体(adalimumab)和阿那白滞素(anakinra)等生物学治疗及中药治疗均显示了新的治疗前景。

In recent years, the substantially increased number of drugs for rheumatoid arthritis （RA） have appeared with the discoveries of the pathogensis and some proimflammatory molecules of RA. Compared with conventional nonsteroidal antiinflammatory drugs, COX-Ⅱ specific inhibitors have a better clinical efficacy and fewer side effects. Good clinical effects can be achieved with the use of early combination of disease-modifying anti-rheumatic drugs therapy. In addition, biological drug therapy such as etanercept,adalimumab, anakinra and herbal medicine for RA have opened a new therapeutical perspec- tlve.